Business
Wellgistics Expands Healthcare Ecosystem with Tollo Health Agreement, Targeting Multi-Billion Dollar GLP-1 and Long COVID Market
Tampa, Florida, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX, the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, has entered into an agreement with Tollo Health, LLC (“Tollo”) to market Tollo’s emerging proprietary suite of novel medical food products for GLP-1 treatment-related side effects, includi
About this update from Wellgistics Health, Inc.
[{"type":"image","alt":"Wellgistics Health, Inc.","displaySize":"","headline":null,"caption":"Wellgistics Health, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":37,"url":"https://media.zenfs.com/en/globenewswire.com/3756275c8f89bb335042b64c61726096"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GD0D_DEMfS50Y9mV91T3bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/3756275c8f89bb335042b64c61726096","width":300,"height":37}},"lazy":false},{"type":"text","content":"Tampa, Florida, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX, the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, has entered into an agreement with Tollo Health, LLC (“Tollo”) to market Tollo’s emerging proprietary suite of novel medical food products for GLP-1 treatment-related side effects, including muscle loss and Long COVID to pharmacies. Tollo is bringing to market novel, proprietary medical food products to address muscle loss and gut discomfort associated with GLP-1 drug use, and persistent viral infection(s), gut discomfort, sarcopenia, immune dysregulation, cellular senescence, endothelial damage and general nutritional support for patients with Long COVID. Tollo’s first marketed product is Galectovid™, a proprietary medical food for the dietary management of Galectin-1 & 3 associated viral infections. Further details on Galectovid™ are available at www.galectovid.com.","length":1104,"tagName":"p"},{"type":"text","content":"“We are excited to partner with the team at Tollo, who bring in-depth scientific and medical knowledge in both the areas of muscle loss and chronic viral infections”, said Jason Lang, Vice President of Business Development of Wellgistics LLC. “We believe that our expansion into medical foods will directly impact our pharmacy clients and support physicians and the patients they serve. Managing the side effects of GLP-1 drugs and the devastating impacts of Long COVID remains a challenge because there are no approved prescription treatment options currently available. It only makes sense to look at natural products, backed by cutting edge scientific research, with n...